Adult-onset dementia disorders represent a challenge for modern medicine. Alzheimer’s disease (AD) represents the most diffused form of adult-onset dementias. For half a century, the diagnosis of AD was based on clinical and exclusion criteria, with an accuracy of 85%, which did not allow for a definitive diagnosis, which could only be confirmed by post-mortem evaluation. Machine learning research applied to Magnetic Resonance Imaging (MRI) techniques can contribute to a faster diagnosis of AD and may contribute to predicting the evolution of the disease. It was also possible to predict individual dementia of older adults with AD screening data and ML classifiers. To predict the AD subject status, the MRI demographic information and pre-existing conditions of the patient can help to enhance the classifier performance. In this work, we proposed a framework based on supervised learning classifiers in the dementia subject categorization as either AD or non-AD based on longitudinal brain MRI features. Six different supervised classifiers are incorporated for the classification of AD subjects and results mentioned that the gradient boosting algorithm outperforms other models with 97.58% of accuracy.

Background: Parkinson’s disease (PD) is the most prevalent neurodegenerative movement disorder and a growing health concern in demographically aging societies. The prevalence of PD among individuals over the age of 60 and 80 years has been reported to range between 1% and 4%. A timely diagnosis of PD is desirable, even though it poses challenges to medical systems. Objective: This study aimed to classify PD and healthy controls based on the analysis of voice records at different frequencies using machine learning (ML) algorithms. Methods: The voices of 252 individuals aged 33 to 87 years were recorded. Based on the voice record data, ML algorithms can distinguish PD patients and healthy controls. One binary decision variable was associated with 756 instances and 754 attributes. Voice records data were analyzed through supervised ML algorithms and pipelines. A 10-fold cross-validation method was used to validate models. Results: In the classification of PD patients, ML models were performed with 84.21 accuracy, 93 precision, 89 Sensitivity, 89 F1-scores, and 87 AUC. The pipeline performance improved to accuracy: 85.09, precision: 92, Sensitivity:91, F1-score: 89, and AUC: 90. The Pipeline methods improved the performance of classifying PD from voice record. Conclusions: Our study demonstrated that ML classifiers and pipelines can classify PD patients based on speech biomarkers. It was found that pipelines were more effective at selecting the most relevant features from high-dimensional data and at accurately classifying PD patients and healthy controls. This approach can therefore be used for early diagnosis of initial forms of PD.

Background: The progressive aging of populations, primarily in the industrialized western world, is accompanied by the increased incidence of several non-transmittable diseases, including neurodegenerative diseases and adult-onset dementia disorders. To stimulate adequate interventions, including treatment and preventive measures, an early, accurate diagnosis is necessary. Conventional magnetic resonance imaging (MRI) represents a technique quite common for the diagnosis of neurological disorders. Increasing evidence indicates that the association of artificial intelligence (AI) approaches with MRI is particularly useful for improving the diagnostic accuracy of different dementia types. Objectives: In this work, we have systematically reviewed the characteristics of AI algorithms in the early detection of adult-onset dementia disorders, and also discussed its performance metrics. Methods: A document search was conducted with three databases, namely PubMed (Medline), Web of Science, and Scopus. The search was limited to the articles published after 2006 and in English only. The screening of the articles was performed using quality criteria based on the Newcastle–Ottawa Scale (NOS) rating. Only papers with an NOS score ≥ 7 were considered for further review. Results: The document search produced a count of 1876 articles and, because of duplication, 1195 papers were not considered. Multiple screenings were performed to assess quality criteria, which yielded 29 studies. All the selected articles were further grouped based on different attributes, including study type, type of AI model used in the identification of dementia, performance metrics, and data type. Conclusions: The most common adult-onset dementia disorders occurring were Alzheimer’s disease and vascular dementia. AI techniques associated with MRI resulted in increased diagnostic accuracy ranging from 73.3% to 99%. These findings suggest that AI should be associated with conventional MRI techniques to obtain a precise and early diagnosis of dementia disorders occurring in old age.

Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by motor impairment, as well as tremors, stiffness, and rigidity. Besides the typical motor symptomatology, some Parkinsonians experience non-motor symptoms such as hyposmia, constipation, urinary dysfunction, orthostatic hypotension, memory loss, depression, pain, and sleep disturbances. The correct diagnosis of PD cannot be easy since there is no standard objective approach to it. After the incorporation of machine learning (ML) algorithms in medical diagnoses, the accuracy of disease predictions has improved. In this work, we have used three deep-learning-type cascaded neural network models based on the audial voice features of PD patients, called Recurrent Neural Networks (RNN), Multilayer Perception (MLP), and Long Short-Term Memory (LSTM), to estimate the accuracy of PD diagnosis. A performance comparison between the three models was performed on a sample of the subjects’ voice biomarkers. Experimental outcomes suggested that the LSTM model outperforms others with 99% accuracy. This study has also presented loss function curves on the relevance of good-fitting models to the detection of neurodegenerative diseases such as PD.

Introduction: In biobanks, participants’ biological samples are stored for future research. The application of artificial intelligence (AI) involves the analysis of data and the prediction of any pathological outcomes. In AI, models are used to diagnose diseases as well as classify and predict disease risks. Our research analyzed AI’s role in the development of biobanks in the healthcare industry, systematically. Methods: The literature search was conducted using three digital reference databases, namely PubMed, CINAHL, and WoS. Guidelines for preferred reporting elements for systematic reviews and meta-analyses (PRISMA)-2020 in conducting the systematic review were followed. The search terms included “biobanks”, “AI”, “machine learning”, and “deep learning”, as well as combinations such as “biobanks with AI”, “deep learning in the biobanking field”, and “recent advances in biobanking”. Only English-language papers were included in the study, and to assess the quality of selected works, the Newcastle–Ottawa scale (NOS) was used. The good quality range (NOS ≥ 7) is only considered for further review. Results: A literature analysis of the above entries resulted in 239 studies. Based on their relevance to the study’s goal, research characteristics, and NOS criteria, we included 18 articles for reviewing. In the last decade, biobanks and artificial intelligence have had a relatively large impact on the medical system. Interestingly, UK biobanks account for the highest percentage of high-quality works, followed by Qatar, South Korea, Singapore, Japan, and Denmark. Conclusions: Translational bioinformatics probably represent a future leader in precision medicine. AI and machine learning applications to biobanking research may contribute to the development of biobanks for the utility of health services and citizens.

Parkinson’s disease (PD) is a progressive neurodegenerative disorder leading to movement impairment, cognitive decline, and psychiatric symptoms. Key manifestations of PD include bradykinesia (the slowness of movement), changes in voice or speech, and gait disturbances. The quantification of neurological disorders through voice analysis has emerged as a rapidly expanding research domain, offering the potential for non-invasive and large-scale monitoring. This review explores existing research on the application of machine learning (ML) in speech, voice, and language processing for the diagnosis of PD. It comprehensively analyzes current methodologies, highlights key findings and their associated limitations, and proposes strategies to address existing challenges. A systematic review was conducted following PRISMA guidelines. We searched four databases: PubMed, Web of Science, Scopus, and IEEE Xplore. The primary focus was on the diagnosis, detection, or identification of PD through voice, speech, and language characteristics. We included 34 studies that used ML techniques to detect or classify PD based on vocal features. The most used approaches involved free speech and reading-speech tasks. In addition to widely used feature extraction toolkits, several studies implemented custom-built feature sets. Although nearly all studies reported high classification performance, significant limitations were identified, including challenges in comparability and incomplete integration with clinical applications. Emerging trends in this field include the collection of real-world, everyday speech data to facilitate longitudinal tracking and capture participants’ natural behaviors. Another promising direction involves the incorporation of additional modalities alongside voice analysis, which may enhance both analytical performance and clinical applicability. Further research is required to determine optimal methodologies for leveraging speech and voice changes as early biomarkers of PD, thereby enhancing early detection and informing clinical intervention strategies.